Skip to main content
. 2026 May 28;18(11):1759. doi: 10.3390/cancers18111759
B2M Beta-2 microglobulin
CTC Circulating tumor cells
ctDNA Circulating tumor DNA
EGFR-TKIs Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
EMT Epithelial-to-mesenchymal transition
HD Healthy donors
ICI Immune checkpoint inhibitors
NSCLC Non-small-cell lung cancer
PB Peripheral blood
PBMC Peripheral blood mononuclear cells
PD Progression of disease
TME Tumor microenvironment
VIM Vimentin